Consistent with the concept that autoimmunity and cancer rejection might represent different facets of the same phenomenon, we observed that polymorphisms protecting against the susceptibility to develop SLE[12,13], such as the IRF5 rs10954213 GG genotype, were significantly more prevalent among patients who did not respond to adoptive TIL therapy. This evidence concerns the gene IRF5 and systemic lupus erythematosus.